During prospective clinical research with 90 patients suffering of Bronchial Asthma (BA) in remission stage (group I) and 90 patients suffering Chronic Obstructive Pulmonary Disease (СOPD) in remission stage (group II) have been stratified into equal subgroups IА, IБ, IВ, IIА, IIБ, IIВ according to the usage of the base inhale therapy. Patients who stopped the base therapy in the period 3-12 month before screening were included into the subgroups “A”; subgroups “B” contained the patients treated regularly with base therapy; subgroups “C” contained subjects excluded base therapy more than one year ago. Supervision duration over each patient made 1 year. It has been shown that the termination of using of base medications leads to increase in consumption of emergency medications and increases probability of the adverse events, but expressiveness of influence of the base therapy cancellation to the listed indicators decreases eventually.
4. Reddel H.K. Lechenie bronhialnoi astmi i ee obostrenii: standartizovannie konechnie pokazateli dlya klinicheskih issledovanii po astme i klinicheskoi praktiki. Oficialnii dokyment ATO / ERO. Chast 2. Ot imeni Rabochei gryppi Amerikanskogo torakalnogo obshestva (ATO) / Evropeiskogo respiratornogo obshestva (ERO) po kontrolu nad bronhialnoi astmoi i ee obostreniyami / H.K. Reddel, D.R. Teilor, E.V. Beitman i dr. // Pylmonologiya. – 2011. - №2. – S. 9-40.
7. Celli B.R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper / B.R. Celli, W. MacNee // Eur. Respir. J. 2004; 23: 932-46.
8. Chen H. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease / H. Chen, M.K. Gould, P.D. Blanc, D.P. Miller at al. // J Allergy Clin Immunol 2007;120:396-402.